Manchikanti L, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part I—evidence assessment. Pain Physician. 2012;15:S1–66.
Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten year perspective. Pain Physician. 2010;13:401–35.
Volkow ND, McLellan TA, Cotto JH. Characteristics of opioid prescriptions in 2009. JAMA. 2011;305:1299–301.
Governale L. Outpatient prescription opioid utilization in the U.S., years 2000–2009. Drug Utilization Data Analysis Team Leader, Division of Epidemiology, Office of Surveillance and Epidemiology. Presentation for U.S. Food and Drug Administration, 22 July 2010.
IMS Institute for Healthcare Informatics. The use of medicines in the United States: Review of 2011; April 2012.
Report of the International Narcotics Control Board 2008. New York: United Nations. 2009.www.incb.org/pdf/annual-report/2008/en/AR_08_English.pdf
Broward County Commission on Substance Abuse. Based on data from the Broward County Appraisal Office and Automation of Reports and Consolidated Orders System (ARCOS); 2009.
Automation of Reports and Consolidated Orders System (ARCOS). US Drug Enforcement Agency; 2010.
Adopted by the American Society of Addiction Medicine Board of Directors; 4/12/2011.
Gold M, Redmond DE, Kleber HD. Clonidine blocks acute opioid withdrawal symptoms. Lancet. 1978;1:929–30.
Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009;12:679–84.
Prochaska JO, DiClemente CC. Transtheoretical therapy: toward a more integrative model of change. Psychother Theory Res Pract. 1982;19(3):276–88.
Wesson DR, Ling W. The Clinical Opioid Withdrawal Scale. J Psychoactive Drugs. 2003;35:253–9.
Zubieta JK, et al. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology. 2000;23(3):326–34.
Kakko J, et al. Buprenorphine improved treatment retention in patients with heroin dependence. Lancet. 2003;361:662–8.
Jones HE, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–31.
Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432–42.
Mattick RP, Ali R, White JM, O’Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;98:441–52.
Ling W, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100:1090–100.
Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. Eur J Clin Invest. 2003;33:824–9.
Ling W, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93:475–86.
Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain. 1997;70(2–3):109–15.